Financial Digest

Goldman: Buy WeightWatchers stock on deal to offer weight-loss drugs

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 51%

Finance Finance Headlines News

Goldman Sachs says WeightWatchers' latest deal could revive the company and help it bring in $1.4 billion by 2025

Launched in 2021, Sequence prescribes weight-loss drugs like Ozempic and Wegovy online while helping patients navigate reimbursement and insurance.

Goldman Sachs estimates that sales for obesity drugs like GLP-1s could reach $30 billion annually by 2032. Analysts said in a Monday note that the potential market for such treatments is around 15 million people in the US today, a number that could grow to 31 million in 2030.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

While the media glorifies obesity. Lol nice try

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in FİNANCE

Finance Finance Latest News, Finance Finance Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Weight Watchers parent’s stock soars after deal to buy weight-management drugs prescriber Sequence closesShares of WW International Inc. which was formerly known as Weight Watchers, soared 25.2% toward a five-week high in premarket trading Tuesday, after the...
Source: MarketWatch - 🏆 3. / 97 Read more »

Goldman Sachs to pay $15 million to CFTC for index-swap violationsGoldman Sachs settled charges Monday with the Commodity Futures Trading Commission that it violated standards related to equity index swap transactions....
Source: MarketWatch - 🏆 3. / 97 Read more »